StockNews.AI
JAGX
StockNews.AI
5 days

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

1. JAGX reported a 35% revenue increase in Q2 2025 over Q1 2025. 2. Clinical trials for crofelemer show promising results, supporting regulatory strategies.

Earnings
-19.11%Current Return
VS
-0.06%S&P 500
$2.5908/14 08:08 AM EDTEvent Start
$2.09508/15 02:34 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The reported revenue growth and positive trial results indicate strong operational momentum for JAGX, similar to instances in the past where revenue growth correlated with stock price increases. The development of a supplemental NDA for crofelemer could attract investor interest and drive future stock price appreciation.

How important is it?

The article presents crucial financial and operational updates that can directly influence JAGX's market perception and performance, especially with the FDA meeting and continued revenue growth.

Why Short Term?

The upcoming investor webcast and immediate positive financial results are likely to influence JAGX's stock price in the near term, as investors react to the recent developments rapidly.

Related Companies

MYTEAXDXCARR
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was equal to the volume in Q2 2024 As announced , initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q2 2025 financials and company updates; Click here to register SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated second-quarter 2025 financial results.

Related News